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Abstract 
Direct-acting antivirals have become widely used for patients with chronic hepatitis C 
virus infection with decompensated cirrhosis. Virological responses are excellent and 
early improvements in liver function, at least in a proportion of patients, have been 
observed but the longer term impact of viral clearance on end-stage liver disease 
complications is unclear.  
Methods: Prospective study of patients with decompensated cirrhosis who received 12 
weeks of all-oral direct-acting antivirals through the English Expanded Access 
Programme. Endpoints were deaths, liver transplantation, hepatocellular carcinoma, 
serious decompensation events, sepsis or hospitalisations, and MELD scores between 
start of therapy to 15 months post treatment start. An untreated cohort of patients was 
retrospectively studied over 6 months for comparison.  
Results: Amongst 317/406 patients who achieved sustained virological response at 24 
weeks post-treatment, there were 9 deaths (3%), 17 new liver cancers (5%), 39 
transplantations (12%) and 52 with serious decompensations (16%), over 15 months.  
When compared to the first six months from treatment start and to untreated patients, 
there was a reduction in incidence of decompensations [30/406 (7%) in months 6-15 
and 72/406 (18%) in months 0-6 for treated patients vs 73/261 (28%) in untreated 
patients). There was no significant difference in liver cancer incidence (10/406 (2.5%) in 
months 6-15 and 17/406 (4%) in months 0-6 for treated patients vs 11/261 (4%) in 
untreated patients).   
*Manuscript
Click here to view linked References
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Conclusions: This study suggests that antiviral therapy in patients with decompensated 
cirrhosis led to prolonged improvement in liver function, with no evidence of paradoxical 
adverse impact nor increase in liver malignancy. 
 
Lay summary 
This is a report of a large group of patients in England who have hepatitis C virus (HCV) 
infection with advanced liver disease. They have been treated with new anti-HCV drugs, 
which cured the infection in the majority. This study looks at their outcomes a year 
following treatment, in terms of deaths, cancers and other complications of advanced 
liver disease. We conclude that in most patients anti-HCV treatment is beneficial even in 
advanced liver disease.  
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Introduction 
All-oral, interferon-free direct-acting antiviral (DAA) therapy for chronic hepatitis C virus 
(HCV) infection has allowed successful treatment of patients with advanced liver 
disease. Worldwide, large numbers of HCV-infected patients with decompensated 
cirrhosis have received antiviral therapy and although sustained virological response 
(SVR) rates are slightly reduced compared to patients with compensated disease, over 
80% of treated patients still achieve viral clearance. Early analysis of patients who 
responded to therapy showed associated improvements in MELD and Child Pugh 
scores [1] [2-4], although some concerns have been expressed that the rate of 
malignancy may not change or may, paradoxically, increase [5, 6]. Previous studies of 
interferon-based therapies have demonstrated that HCV clearance improves liver 
fibrosis, even in cirrhosis [7]. Moreover, patients who achieved SVR had reduced 
mortality, complications of cirrhosis and hepatocellular carcinoma compared to 
untreated patients or those who failed to achieve SVR [8-10]. However such studies 
involved patients with relatively ‘early’ cirrhosis and it remains unclear whether these 
long term benefits will be seen in patients treated for more advanced disease.  Although 
there is little data on long term outcomes, international guidelines recommend that 
patients with decompensated cirrhosis should be urgently treated with interferon-free 
DAA therapy, regardless of eligibility for liver transplantation [11, 12].  
Chronic HCV infection is the main indication for liver transplantation in the Western 
world, and universally recurs causing accelerated disease progression in the liver graft. 
Given the shortage of donor organs and costs of liver transplantation, DAA treatment 
may reduce the need for transplantation in patients with advanced cirrhosis and allow 
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alternative uses for scarce organs. Pooled analysis of over 800 patients with 
decompensated cirrhosis showed that 60% of patients had an improvement in MELD 
score from baseline following therapy, but 23% deteriorated, at post treatment weeks 4 
to 12 [13]. The magnitude of improvement varied with a median of 2 MELD points. It is 
unclear whether this early change is clinically meaningful. Perhaps more importantly, 
minor reductions in MELD may adversely affect access to liver transplantation, if a 
patient no longer meets transplant criteria but is insufficiently improved with a reduced 
quality of life (so called ‘MELD purgatory’). In such cases, therapy may not be beneficial.  
We recently published data on the virological and clinical outcomes of patients with 
decompensated cirrhosis treated on the English Expanded Access Programme (EAP) 
with 12 weeks of sofosbuvir  and a NS5A inhibitor with or without ribavirin [14]. 
Consistent with other studies, the majority of patients successfully achieved viral 
clearance associated with MELD improvements by post treatment week 12. To assess 
the impact of antiviral therapy in patients with decompensated cirrhosis, the study 
compared treated patients to a retrospective cohort of patients with decompensation 
who were untreated for 6 months prior to the availability of DAAs. Treated patients had 
fewer decompensations, reduced deterioration in MELD, and overall adverse events, 
although there were no significant differences in rates of death, liver transplantation or 
hepatocellular carcinoma [14].  To address the longer-term benefits of successful HCV 
clearance, here we report the outcomes in the same patient cohort followed up for one 
year after completion of therapy.  
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Patients and Methods 
Patients who received DAA therapy through the English EAP were enrolled into the 
HCV Research UK (HCVRUK) registry for prospective data collection. Patients who 
started treatment between 1 April and 11 November 2014 were studied. Details of the 
EAP treatment and patient selection criteria were previously published [14]. In brief, 
treatment consisted of 12 weeks of sofosbuvir with ledipasvir or daclatasvir, with or 
without ribavirin. Treatment choice was according to local multidisciplinary meeting 
decisions by experienced clinicians. Eligible patients included those with past or current 
decompensated cirrhosis (with ascites, variceal bleed or encephalopathy), Child Pugh 
score B7 or above, extra-hepatic HCV manifestations or exceptional circumstances 
which were determined by panel review. Presence of hepatocellular carcinoma was not 
an indication for treatment in the EAP unless one of the above criteria was also met.  
An untreated cohort of patients with decompensated HCV cirrhosis were studied for 6 
months to compare early outcomes with patients who underwent treatment on the EAP. 
They were not studied beyond 6 months of follow-up as data was retrospectively 
collected. Untreated patients were registered in HCVRUK either at least 6 months prior 
to the national start date of the EAP (1 April 2014), or 6 months before initiation of 
treatment for those patients who subsequently received DAAs. Further details on this 
comparator cohort have been described [14].   
The study conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by the institution’s human research committee. Ethics 
approval for HCVRUK was given by NRES Committee East Midlands – Derby 1 
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(Research Ethics Committee reference 11/EM/0314) and informed consent was 
obtained from each patient included in the study. Patients in the EAP who declined data 
collection (N=13) were treated but were excluded from this analysis. 
 
Outcome measures 
Data on virological response and clinical outcomes at 12 weeks post treatment on 
consenting patients treated in the EAP was previously published [14]. Here we focus on 
the clinical outcomes in patients with decompensated cirrhosis followed for up to a year 
post completion of therapy (total follow up 15 months since start of therapy). Data was 
collected for the period post treatment week 12 to month 12 (month 6 to 15), via 
standardised electronic forms. Sites were individually re-contacted by the central study 
team with any missing or invalid responses, to ensure completeness and accuracy of 
collected data. This data was combined with earlier data from treatment start to month 6.  
Viral loads at 24 weeks post treatment end or later were collected. We assessed the 
proportion of patients who achieved SVR24, and those with late relapse after initial 
undetectable viral load at post treatment week 12. All who relapsed were offered 
retreatment with 24 weeks therapy.  
The following primary clinical endpoints were collected: deaths, liver transplantations 
and hepatocellular carcinoma at 15 months (3 months on treatment, 12 months post-
treatment). Endpoints were calculated as 15 months from treatment start date, to 
account for premature treatment discontinuations.  
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For patients who achieved SVR24, the following secondary endpoints were measured: 
serious adverse events (decompensation, sepsis, hospitalisation for any cause) 
between month 6 and 15, MELD scores at 15 months (for non-transplanted patients 
only).  For patients who did not attend clinic at month 15, laboratory data from visits 
within 1 month of the timepoint were included.  Patients who did not achieve SVR24 
were not included. SVR24 was defined as undetectable HCV RNA (measured at local 
laboratories with a lower limit of quantification of <30iu/mL) at 24 weeks post-treatment. 
Where there was no result available at post-treatment week 24 but subsequent viral 
load was detectable, it was assumed that the patient had not achieved SVR24. MELD 
scores were calculated using results provided by local accredited laboratories. Serious 
adverse event was defined as life-threatening, requiring hospitalisation or prolonged 
existing hospitalisation, resulting in persistent or significant disability, incapacity or death.  
Statistical analysis was performed using Graphpad Prism 5. The following statistical 
tests were performed: chi-squared test (for comparison of proportions), T-test (for 
comparison of means) and log rank test (for comparison of survival).  
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Results 
Patient population 
A total of 480 patients received antiviral therapy through the EAP between the start of 
the programme on 1 April 2014 to 11 November 2014 – 467 (97.3%) patients consented 
to provide data to the HCVRUK registry and 406 (87%) patients had decompensated 
cirrhosis and/or Child Pugh score ≥B7, without previous liver transplantation, at 
treatment start. Sixty-one (13%) patients were treated for extrahepatic HCV disease or 
aggressive HCV recurrence in liver grafts.  
Table 1 shows the demographics and baseline liver disease of patients with 
decompensation. The majority (295/406, 72.7%) were Child Pugh B; 41 patients (10.1%) 
were Child Pugh C. The remaining 70 patients (17.2%) had Child Pugh A disease at 
baseline but a past history of liver decompensation. Most patients had significant portal 
hypertension represented by a median platelet count of 75x109/L.  
Virological outcomes 
SVR12 was achieved in 329 out of 406 patients (81.0%), including 4 patients originally 
classified as non-SVR12 because no virology result was available, but who on further 
follow up, were shown to be HCV RNA negative. Four patients relapsed after having a 
HCV RNA negative result at post treatment week 12 and a further 8 died in the follow-
up period after achieving SVR12. Therefore 317 (78.1%) patients achieved SVR24. Of 
note there were no late relapses after post treatment week 12 amongst patients without 
baseline decompensated cirrhosis.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
Amongst the 89 patients who did not achieve SVR24, 53 had virological failure (49 
known before post treatment week 12 and 4 late relapsers), 14 patients died before 
reaching post treatment week 12, and another 12 between post treatment 12-24 weeks. 
Ten patients had no available viral results at post treatment week 24 although clinical 
outcomes data was still provided. See supplementary table 1 for SVR24 according to 
genotype and treatment regimen.  
Of the 53 patients with virological failure, 21 had viral relapse by post treatment week 4, 
24 patients by post treatment week 12, and 4 relapsed after post treatment week 12. 
Three patients did not clear virus by the end of therapy and one patient without a known 
virological result at post treatment week 12 subsequently had documented relapse.  
Forty-five of the patients with viral relapse were offered re-treatment with a 24 week 
course of the same drug regime (switching NS5A inhibitor was not supported by the 
funders of the EAP), the outcomes of which will be reported separately. Eight patients 
declined re-treatment. 
 
Outcomes after 15 months in patients with decompensated cirrhosis  
Mortality 
In the 406 patients with decompensated cirrhosis there were 40 deaths over 15 months 
(9.9%) – 9 patients died who achieved SVR24 (2.8%), which was not statistically 
different to patients with known virological failure (3/53, 5.7%, p=0.28) (Table 2). 
Although virological failure was predominantly seen in genotype 3 infected patients, the 
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proportion who died did not differ between genotypes – there were 9 deaths amongst 24 
genotype 1 infected patients without SVR24, compared to 21 deaths amongst 60 
genotype 3 infected patients without SVR24 (37.5% vs 35.0%, p=0.83). Figure 1 shows 
the survival rates over the study period.   
 
Development of Liver Cancer 
At treatment baseline, 29 of 406 total patients had a history of HCC (median days 
between diagnosis and DAA start was 287 days). Eighteen of these patients achieved 
SVR24 (Table 1). Two patients with pre-existing liver cancer history developed a new 
HCC (at 20 and 26 weeks from treatment start), both achieved SVR24. There were no 
recurrent HCCs amongst patients with previous cancer who did not achieve SVR24.  
Amongst 317 patients who achieved SVR24, 17 (5.4%) developed a liver cancer (Table 
2) over the follow up period of 15 months (15 de novo and 2 recurrent). Five of the 17 
(29.4%) new liver cancers developed in patients who achieved SVR24 occurred early, 
within 3 months of commencing treatment. There was a reduction (of borderline 
significance) in new cancer rates over 15 months between patients with and without 
SVR24 (17/317, 5.4% vs 10/89, 11.2%, p=0.049) in patients with decompensated 
cirrhosis (hazard ratio 0.33, 95% CI 0.13 - 0.87) (see figure 2). This compares with 
11/261 (4.2%) in untreated patients over 6 months.  
 
Other outcomes 
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Table 2 shows the outcomes for patients followed up for 15 months. Amongst the 317 
patients who achieved SVR24, 39 (12.3%) received a liver transplant. Forty-six patients 
experienced serious decompensation between months 0-6 (14.5%) which was markedly 
reduced in months 6-15 (16/317, 5.0%) (p=0.00006). Supplementary table 2 shows the 
details of these events with incidences of decompensations, sepsis and all-cause 
hospitalisations which were graded as serious adverse events.  
For patients who achieved SVR24, 135 (42.6%) experienced at least one serious 
adverse event (death, transplant, liver cancer, decompensation, sepsis or 
hospitalisation), therefore the transplant-free, adverse-event free survival over 15 
months was 57.4%. The group with adverse events contained a significantly higher 
proportion of patients with Child Pugh C disease at baseline – 24/135 (17.8%) for 
patients with adverse events and 5/182 (2.7%) for patients without adverse events 
(p<0.0005) (see Table 1). Figure 3 shows that adverse events were most frequent 
during the treatment period, and decreased over time.   
Earlier we published on the baseline characteristics of the untreated and treated 
patients, showing that the two cohorts were similar apart from a higher proportion of 
patients using alcohol (of any amount) at baseline amongst untreated patients [14]. 
Supplementary table 3 illustrates that after excluding active alcohol users, adverse 
outcomes remained less frequent in treated compared to untreated patients. Amongst 
untreated patients who subsequently received DAAs when they became available, and 
were studied as the treated cohort at least six months later, there were numerically but 
not statistically significantly lower incidences of liver cancers and decompensations 
following treatment.  
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We previously proposed a model using baseline age and albumin to predict adverse 
outcomes at 6 months. Table 3 shows the proportion of patients without adverse 
outcomes at month 15 based on age and serum albumin at treatment start, however 
these baseline factors did not discriminate the likelihood of developing adverse events 
or not. We did not include MELD score change into the model due to the limited number 
of available comparative scores. 
  
MELD scores for patients with decompensated cirrhosis who achieved SVR24 
The mean MELD score change from baseline at month 6 was -0.83 +/- 0.14 
(improvement) and +0.51 +/- 0.4 at month 15 (deterioration) (p<0.0001) based on 282 
patients with available comparative scores at month 6 and 74 patients at month 15. 
Supplementary figure 1 shows the waterfall plots for MELD score changes between 
baseline and month 6 and month 15 for non-transplanted patients who achieved SVR24. 
MELD improvement was observed in patients with higher baseline score (see 
supplementary table 4) but even in for those with baseline MELD >15 the margin of 
improvement was smaller at 15 months than at 6 months. Supplementary table 5 shows 
that based on the small number of available results, there were no patients with 
baseline MELD <9 who worsened to above 15; for the majority group with baseline 
MELD 10-14 there were similar proportions who improved or deteriorated but 48.8% 
had no significant change in MELD at month 15.  
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Discussions 
The availability of highly effective all-oral antiviral regimens for patients with chronic 
HCV infection has transformed the treatment options for infected patients and most 
patients can now achieve viral clearance. For patients with advanced liver disease it is 
unclear whether viral eradication is beneficial and there are some reports suggesting 
that it may be harmful. Indeed the definition of benefit following viral clearance, whether 
it is patient survival, access to transplantation or avoidance of complications, is 
debatable.  
To evaluate the potential risks and benefits of antiviral therapy in patients with end 
stage liver disease we examined medium term outcomes in the English Expanded 
Access Programme. This involved a well-studied, prospectively enrolled cohort of 
patients managed by experienced clinicians in a limited number of centres. Data 
collection was to clinical trial standards although external audit was not performed. 
Although observational studies in non-clinical trial conditions may be confounded by 
subject or clinician non-compliance, the patient cohort in this study all had advanced 
liver disease requiring regular medical intervention and the treating centres were all 
experienced in data handling techniques and were provided with support and resources 
from the central administration. We therefore believe that our dataset is likely to be 
accurate and complete with minimal errors from reporting or attendance failure. 
One limitation of the study is the choice of control subjects – untreated patients with 
decompensated cirrhosis were selected based on the same criteria as treated patients, 
from the same registry, but were not otherwise matched. Treated and untreated patients 
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had similar demographics and baseline liver disease, apart from the proportion of active 
alcohol users which was higher in untreated patients. Excluding patients using any 
amount of alcohol at baseline, who had additional risks for disease progression and 
potentially poorer engagement with medical input, treated patients remained with fewer 
decompensations and total adverse events compared to untreated [14]. Although 
patients during treatment were followed-up more closely, all patients were regularly 
reviewed due to their advanced liver disease. The study evaluated serious adverse 
events which were actively monitored for (all patients were offered HCC surveillance) or 
resulted in hospitalisations. Therefore reporting of such events between treated and 
untreated patients were not likely to be biased by differences in the frequency of routine 
follow-up. The majority of the untreated cohort subsequently received DAAs when they 
became available, and about half were included in the treated cohort. Thus the same 
patients were studied at least six months later, during their treatment period, and there 
was no increase in the incidences of decompensations and liver cancers.  
Recent studies highlighting the possibility of an increased incidence or recurrence of 
liver malignancy in patients with decompensated cirrhosis who achieve viral clearance 
with DAA regimens has led some to question the value of treating such patients [5, 6]. 
In the English EAP, patients with liver cancer were not indicated for treatment unless 
they had decompensated cirrhosis. We did not see any evidence of an increase in liver 
cancer during therapy and the following 12 months. Nearly a third of the newly detected 
liver cancers occurred in the first 3 months of therapy, suggesting this was growth from 
cancers which were radiologically undetectable at treatment baseline, rather than de 
novo development. There is potential bias that in a cohort of patients with 
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decompensated cirrhosis, development or detection of liver cancer is masked by death 
driven by advanced liver disease. We observed a reduction in cancer rates in patients 
with SVR compared to virological failure, but the relatively short duration of follow up 
and the low incidence of such events prevent a clear conclusion at this stage.   
In the interferon era, antiviral therapy in patients with cirrhosis was associated with 
reduced hepatocellular carcinoma [9]. Large cohorts such as HALT-C have 
demonstrated that reduced cancer development may be an effect of interferon, which 
has anti-tumour properties, rather than viral clearance alone, although this was only 
observed after four years from treatment [15]. The magnitude of the impact of clearing 
HCV with DAAs on liver cancers may require data pooling from studies with longer 
follow-up, and may differ depending on the degree of cirrhosis or whether there is 
previous history of HCC. The reduction in liver cancer rates from 4% in 261 untreated 
patients over 6 months to 1.9% over 9 months after achieving viral clearance in 317 
successfully treated patients reassures us that induction of liver cancer in our patients 
did not occur.  
The long term benefits of viral eradication on liver function and the complications of 
portal hypertension remain unclear. However in our cohort there was a marked 
reduction in liver related serious adverse events in those patients who cleared virus, 
with decreasing adverse events rates over time.  We speculate that patients will 
continue to benefit long term although further data will be required to confirm this.  
The value of antiviral therapy in patients with decompensated cirrhosis will remain a 
subject for debate until very large cohorts have been evaluated for extended periods of 
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time. Our data on 12 months follow up after treatment of a large English cohort indicates 
that there are benefits for many patients, although in patients with Child Pugh C disease 
viral clearance may have the least impact on liver complications. In our view it is 
important that liver transplantation remains available for patients with very advanced 
disease who achieve viral clearance, as such patients may not improve to a level 
commensurate with a high quality of life.  
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Tables 1-3 
Table 1. Baseline characteristics of patients according to treatment outcomes. 
Virological failure included all patients with a detectable viral load at post treatment 
week 24 or before, including re-treated patients. Non-SVR24 included in addition 
patients who died before post treatment week 24 or without available viral load. Serious 
adverse events included all deaths, transplants, HCCs, decompensations, sepsis and 
hospitalisation to month 15. 
 
Baseline 
characteristic 
All 
decompensated 
 
SVR24 Non-SVR24 Virological 
failure 
SVR 24 – 
serious 
adverse 
events  
SVR 24 – no 
serious 
adverse 
events 
All 
N (%) 
406 317 (78.1%) 89 (21.9) 53 (13.1) 135 (42.6%) 182 (57.4%) 
Sof/LDV 18 (4.4) 12 (3.8) 6 (6.7) 4 (7.5) 7 (5.2%) 5 (2.7%) 
Sof/LDV/RBV 228 (56.2) 187 (59.0) 41 (46.1) 30 (56.6) 78 (57.8%) 109 (59.9) 
Sof/DCV 11 (2.7) 7 (2.2) 4 (4.5) 1 (1.9) 5 (3.7%) 2 (1.1%) 
Sof/DCV/RBV 149 (36.7) 111 (35.0) 38 (42.7) 18 (34.0) 45 (33.3%) 66 (36.3%) 
Genotype 1  198 (48.8) 174 (54.9) 24 (27.0) 11 (20.8) 75 (55.6%) 99 (54.4%) 
Genotype 3 171 (42.1) 111 (35.0) 60 (67.4) 39 (73.6) 45 (33.3%) 66 (36.3%) 
Other genotypes 37 (9.1) 32 (10.1) 5 (5.6) 3 (5.7) 15 (11.1%) 17 (9.3%) 
Age (years)  
median, range 
54, 28-79 54, 28-79 52, 30-74 52, 33-72 
 
54, 33-76 55, 28-79 
Bilirubin (µmol/L) 
median, range 
29, 4-433 28, 4-311 34, 7-433 
 
33, 7-148 30, 4-311 26, 6-90 
Albumin (g/L) 
median, range 
31, 17-55 31, 17-49 29, 21-55 30, 21-40 31, 17-45 32, 17-49 
Platelets (x109/L) 
median, range 
75, 3-321 75, 3-321 76, 20-277 76, 20-277 74, 20-237 76, 3-321 
MELD 
median, range 
12, 7-32 11, 7-32 13, -25 12, 8-23 12, 7-32 11, 7-21 
Child Pugh B 295 (72.7) 225 (71.0) 70 (78.7) 42 (79.2) 88 (65.3%) 137 (75.3%) 
Child Pugh C 41 (10.1) 29 (9.1) 12 (13.5) 5 (9.4) 24 (17.8%) 5 (2.7%) 
Baseline HCC 29 (7.1) 18 (5.7) 11 (12.4) 9 (17.0) 13 (9.6%) 5 (2.7%) 
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Footnote: Since the earlier publication [4], 3 additional patients were confirmed as 
transplanted prior to DAA therapy, including one registered for therapy pre-transplant, 
grafted then initiated treatment. These patients were re-defined as post-transplant at 
treatment baseline, therefore 406 instead of 409 patients were included in this study.   
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Table 2. Deaths, hepatocellular carcinomas (HCC), orthotoptic liver transplants 
(OLT) and decompensations over 15 months for all treated patients according to 
treatment outcomes, compared to patients untreated for HCV (data for untreated 
patients derived from [4]). Note all deaths up to post treatment week 24 were defined as 
non-SVR24. Decompensation events were recorded for patients with SVR24 only. 
 
Adverse Event Untreated 
N=261 
All treated 
N = 406 
 Month 0-6 Month 0 - 6 Month 6 - 15 Overall 
Died 13 (5.0%) 14 (3.4%) 26 (6.4%) 40 (9.9%) 
HCC 11 (4.2%)Ɨ 17 (4.2%) 10 (2.5%) 27 (6.7%) 
OLT 10 (3.8%) 29 (7.1%) 17 (4.2%) 46 (11.3%) 
Decompensation 73 (28.0) 72 (17.7%) 30 (7.4%) 87 (21.4%) 
 
 
 
Adverse 
Event 
SVR24 
N = 317 
Non-SVR24 
N=89 
Virological failure 
N = 53 
 Month 0 
- 6 
Month 6 
- 15 
Overall Month 
0 – 6 
Month 6 
- 15 
Overall Month 
0 – 6 
Month 6 
- 15 
Overall 
Died 0 (0.0%) 
 
9 (2.8%) 9 (2.8%) 14 
(15.7%) 
17 
(19.1%) 
31 
(34.8%) 
0 (0%) 3 (5.7%) 
* 
3 (5.7%) 
HCC 11 
(3.5%) 
 
6 (1.9%) 17 (5.4%) 6 (6.7%) 4 (4.5%) 
** 
10  
(11.2%) 
3 (5.7%) 3 (5.7%) 6 
(11.3%) 
OLT 27 
(8.5%) 
12 
(3.8%) 
 
39 
(12.3%) 
2 
(2.2%) 
*** 
5 (5.6%) 7 (7.9%) 1 (1.9%) 5 (9.4%) 6 
(11.3%) 
Decomp-
ensation 
46 
(14.5%) 
16 
(5.0%) 
52 
(16.4%) 
26 
(29.2%) 
- 
 
- - - - 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
26 
 
Footnote:  
* denotes two patients who did not have known virological outcomes at 24 weeks post-
treatment but had reported deaths, one of the two patients (marked by **) also had a 
new liver cancer 
*** denotes a patient transplanted by month 6 who did not have a known virological 
outcome at 24 weeks post-treatment 
Ɨ  figure updated from earlier publication 
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Table 3. Proportion of patients without adverse events (death, transplantation, 
liver cancer, decompensation, sepsis or hospitalisations) according to baseline 
characteristics (total 182 patients out of 317 who achieved SVR24).  
 
    N No adverse events (n)  
Age <65 Albumin >/= 35 74 47 63.5% 
Age <65 Albumin <35 212 120 56.6% 
Age >/=65 Albumin <35 21 10 47.6% 
Age >/=65 Albumin >/= 35 10 5 50.0% 
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Figure legends 
 
Fig. 1. Survival of patients over 15 months. (A) Survival in patients treated and 
untreated (log rank p=0.32). (B) Survival in treated patients with SVR24 and virological 
failure (log rank p=0.38). Note by definition no deaths occurred before month 9 (post-
treatment week 24) in both groups.  
 
Fig. 2. Development of new hepatocellular carcinoma over 15 months. (A) New 
hepatocellular carcinoma in untreated and treated patients (log rank p=0.98). (B) New 
hepatocellular carcinoma in patients with and without SVR24 (log rank p=0.02)  
 
Fig. 3. Combined adverse event rate (death, liver transplant, HCC, 
decompensation, sepsis, all-cause hospitalisation) per person over time, for 
patients with SVR24 (n=307). Error bars represent 95% confidence intervals.  
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